Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting

Interim results of C-SWIFT, a Phase 2 study evaluating ultra-short treatment durations of grazoprevir/elbasvir (MK-5172/MK-8742) plus sofosbuvir, to be presented
Results from the C-WORTHy study, a Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742) across multiple patient populations, including difficult-to-cure, to be presented
Wednesday, October 8, 2014 11:13 am EDT

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical studies of the company’s investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) are scheduled to be presented at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting®. The meeting is scheduled to take place at the John B. Hynes Veterans Memorial Convention Center in Boston, Mass., from Nov. 7 – 11, 2014.

“Tremendous progress has been made in recent years in the understanding of chronic hepatitis C and its treatment, but it is important that we continue to advance the development of therapies to treat diverse populations of HCV-infected patients,” said Dr. Eliav Barr, vice president, Infectious Diseases, Merck Research Laboratories. “Merck’s broad and systematic hepatitis C clinical development program is designed with this goal in mind, and is generating important insights into the potential of grazoprevir/elbasvir across multiple viral genotypes and patient populations."
New data will also be presented for MK-3682 (formerly IDX21437), an investigational oral nucleotide prodrug NS5B inhibitor acquired earlier this year by Merck as part of its purchase of Idenix Pharmaceuticals.

Key Presentations of Grazoprevir/Elbasvir
Data from clinical trials evaluating grazoprevir/elbasvir will be the subject of two oral presentations, as well as three poster presentations, including a late-breaking abstract:
Presentation of MK-3682 (IDX21437) Data
For abstracts and program information, please visit:

About Grazoprevir/Elbasvir
Grazoprevir/elbasvir is an investigational, oral, once-daily, fixed-dose combination chronic HCV treatment, consisting of grazoprevir (MK-5172), an investigational oral, once-daily HCV NS3/4A protease inhibitor, and elbasvir (MK-8742), an investigational oral, once-daily HCV NS5A replication complex inhibitor. In October 2013, Merck announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to grazoprevir/elbasvir for treatment of chronic HCV infection. Breakthrough therapy is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

Read complete release here

Labels: , , , ,